

# COVID-19 VACCINATION SCHEDULE AND DOSING


## AGES 5 TO <6 YEARS

### UNVACCINATED

dose/injection volume

**Moderna Bivalent:**  
(Do NOT dilute before use)  
Dark Blue Cap (gray label)

**Pfizer Bivalent:**  
(dilute before use)  
Orange Cap



### PREVIOUSLY VACCINATED

dose/injection volume

Previously Received COVID-19 Vaccines

**Moderna Bivalent:**  
(Do NOT dilute before use)  
Dark Blue Cap (gray label)  
Dark Pink Cap (yellow label)

**Pfizer Bivalent:**  
(dilute before use)  
Orange Cap



### Immunocompromised Guidance for Pfizer-BioNTech

For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

### Immunocompromised Guidance for Moderna

For individuals with certain kinds of immunocompromise 6 months through 5 years of age who have received two 0.25 mL doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent), an additional 0.25 mL dose of Moderna COVID-19 Vaccine, Bivalent (vial with a dark blue cap and a label with a gray border) may be administered at least 1 month following the most recent dose; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual's clinical circumstances.

### Additional Considerations

An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the [CDC's Guidance](#) for latest updates and information on who is considered moderately or severely immunocompromised.

Funding for this project was made possible by the Office of Disease Control, through the Illinois Department of Public Health.